Search results
May 13, 2024 · HCPCS code G0327, Colorectal cancer screening; blood-based biomarker, became effective January 19, 2021, for blood-based biomarker test.Over the last several years, blood-based biomarker tests have emerged as another potential non-invasive option for the early detection of colorectal cancer (CRC).
May 24, 2024 · An FDA panel on Thursday endorsed a blood-based test for colorectal cancer (CRC) screening in adults 45 years and older at average risk for the disease, putting aside concerns over the...
May 21, 2024 · The clinical validation cohort showed a clinical performance of the investigational blood-based test for CRC screening, demonstrating nearly 80% sensitivity for CRC and more than 90% specificity for non-advanced colorectal neoplasia (ACN). “The study suggests that this blood test could offer a convenient and effective screening option for ...
May 8, 2024 · May 8, 2024. ColoSense is expected to launch later this year or in early 2025. The US Food and Drug Administration (FDA) has approved ColoSense, a noninvasive colorectal cancer screening...
May 22, 2024 · The investigational blood-based screening test demonstrated a 79.2% sensitivity for detecting CRC and a 91.5% specificity for identifying the absence of advanced colorectal neoplasia (non-ACN), according to the results presented during Digestive Disease Week 2024, May 18-21, 2024, in Washington, DC. 1. “The study suggests that this blood test ...
May 27, 2024 · Gastrointestinal cancer is the fourth most common cancer in the U.S., according to the National Cancer Institute. Shelley C. Safian, PhD, RHIA, CCS-P, CPC-I, COC, writes about ICD-10-CM coding for colon cancer screening and CPT coding for diagnostic colonoscopies.
May 7, 2024 · May 7, 2024. Geneoscopy has announced that the U.S. Food and Drug Administration (FDA) approved its noninvasive colorectal cancer screening test, ColoSense. ColoSense is a screening test for adults, 45 years of age or older, who are at average risk for developing colorectal cancer (CRC).
